Status:
NOT_YET_RECRUITING
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Florida Department of Health
Conditions:
Cervical Cancer
Human Papilloma Virus (HPV)
Eligibility:
FEMALE
18-89 years
Brief Summary
The goal of this study is to test two commercially available technologies for their ability to detect treatment response in patients with cervical cancer following surgery, radiation, and chemotherapy...
Eligibility Criteria
Inclusion
- 18 years and older
- HPV-associated squamous cell, adenocarcinoma, or adenosquamous cancers of the uterine cervix with evaluable disease
- Diagnosed with American Joint Committee on Cancer (AJCC) stage I or higher, or metastatic disease.
- Presence of evaluable disease on pre-treatment standard of care imaging with plans to obtain serial post-treatment standard of care imaging
- Agree to perform the required research-related blood tests and cervical mucous testing.
Exclusion
- Unable to consent or refusal to sign a consent form
- Not meet any inclusion criteria
- Unable to comply with follow up scheduling.
- Diagnosed with a synchronous malignancy requiring cancer-directed therapy
Key Trial Info
Start Date :
December 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT07214584
Start Date
December 15 2025
End Date
December 31 2026
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32610